Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2010 1
2011 1
2012 2
2013 3
2014 2
2015 5
2016 2
2017 4
2018 3
2019 1
2020 5
2021 9
2022 5
2023 4
2024 8
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

52 results

Results by year

Filters applied: . Clear all
Page 1
Providers' mediating role for medication adherence among cancer survivors.
Trogdon JG, Amin K, Gupta P, Urick BY, Reeder-Hayes KE, Farley JF, Wheeler SB, Spees L, Lund JL. Trogdon JG, et al. PLoS One. 2021 Nov 29;16(11):e0260358. doi: 10.1371/journal.pone.0260358. eCollection 2021. PLoS One. 2021. PMID: 34843550 Free PMC article.
Changes in provider team complexity explained only small changes in medication adherence. Provider team effects were statistically insignificant in 13 of 17 analytic samples with significant changes in adherence. ...CONCLUSIONS: Increased complexity in the provider …
Changes in provider team complexity explained only small changes in medication adherence. Provider team effects were statistically in …
Trends, characteristics, race, and ethnicity associated with nonadherence to antidepressants among breast cancer survivors with depression.
Chang CY, Park H, Hincapie-Castillo JM, Heldermon CD, Diaby V, Yang S, Wilson DL, Lo-Ciganic WH. Chang CY, et al. J Manag Care Spec Pharm. 2023 Apr;29(4):431-445. doi: 10.18553/jmcp.2023.29.4.431. J Manag Care Spec Pharm. 2023. PMID: 36989452 Free PMC article.
However, little is known about the extent of and trends in antidepressant nonadherence among breast cancer survivors with depression, which may impact adherence to breast cancer treatment, potentially leading to breast cancer recurrence and other adverse outcomes. ...
However, little is known about the extent of and trends in antidepressant nonadherence among breast cancer survivors with depression, which …
Changes in chronic medication adherence in older adults with cancer versus matched cancer-free cohorts.
Lund JL, Gupta P, Amin KB, Meng K, Urick BY, Reeder-Hayes KE, Farley JF, Wheeler SB, Spees L, Trogdon JG. Lund JL, et al. J Geriatr Oncol. 2021 Jan;12(1):72-79. doi: 10.1016/j.jgo.2020.04.012. Epub 2020 May 15. J Geriatr Oncol. 2021. PMID: 32423699 Free PMC article.
OBJECTIVES: A cancer diagnosis can influence medication adherence for chronic conditions by shifting care priorities or reinforcing disease prevention. ...In older adults with breast and prostate cancer cohorts, changes in adherence for all medications were similar …
OBJECTIVES: A cancer diagnosis can influence medication adherence for chronic conditions by shifting care priorities or reinforcing d …
The Healthy User Effect in Pharmacoepidemiology.
Olawore O, Stϋrmer T, Glynn RJ, Lund JL. Olawore O, et al. Am J Epidemiol. 2024 Sep 11:kwae358. doi: 10.1093/aje/kwae358. Online ahead of print. Am J Epidemiol. 2024. PMID: 39270671
Addressing the healthy adherer effect due to continued conditioning on adherence over the duration of a study is more challenging as methods to mitigate it require the ability to predict adherence, which is often difficult using databases common in pharmacoepidemiol …
Addressing the healthy adherer effect due to continued conditioning on adherence over the duration of a study is more challenging as …
Patterns of first-line targeted therapy utilization and adherence among older adults diagnosed with metastatic renal cell carcinoma.
Hicks BM, Chun DS, Peacock Hinton S, Hsu CD, Tan HJ, Lund JL. Hicks BM, et al. J Geriatr Oncol. 2022 Apr;13(3):325-333. doi: 10.1016/j.jgo.2021.11.006. Epub 2021 Nov 12. J Geriatr Oncol. 2022. PMID: 34782282
We assessed the initiation of first-line targeted therapy within four months of diagnosis and persistence and adherence to targeted therapy, using the proportion of days covered (PDC). Multivariable logistic regression yielded adjusted odds ratios (ORs) and 95% confidence …
We assessed the initiation of first-line targeted therapy within four months of diagnosis and persistence and adherence to targeted t …
Polypharmacy and medication use by cancer history in a nationally representative group of adults in the USA, 2003-2014.
Hsu CD, Nichols HB, Lund JL. Hsu CD, et al. J Cancer Surviv. 2022 Jun;16(3):659-666. doi: 10.1007/s11764-021-01059-x. Epub 2021 May 25. J Cancer Surviv. 2022. PMID: 34032998
Survivors may experience greater medication burden than the general population, increasing concerns for polypharmacy and subsequent risks of drug interactions and non-adherence. METHODS: Using the National Health and Nutrition Examination Survey (NHANES) data from 2003 to …
Survivors may experience greater medication burden than the general population, increasing concerns for polypharmacy and subsequent risks of …
Comparison of Approaches for Measuring Adherence and Persistence to Oral Oncologic Therapies in Patients Diagnosed with Metastatic Renal Cell Carcinoma.
Chun DS, Hicks B, Hinton SP, Funk MJ, Gooden K, Keil AP, Tan HJ, Stürmer T, Lund JL. Chun DS, et al. Cancer Epidemiol Biomarkers Prev. 2022 Apr 1;31(4):893-899. doi: 10.1158/1055-9965.EPI-21-0341. Cancer Epidemiol Biomarkers Prev. 2022. PMID: 35064061
BACKGROUND: Adherence and persistence studies face several methodologic difficulties, including short-term mortality. We compared approaches to quantify adherence and persistence to first line (1L) oral targeted therapy (TT) in patients diagnosed with metastatic ren …
BACKGROUND: Adherence and persistence studies face several methodologic difficulties, including short-term mortality. We compared app …
Adherence to prescription proton pump inhibitor therapy amongst individuals diagnosed with Barrett's esophagus.
Gaber CE, Abdelaziz AI, Sarker J, Lund JL, Dellon ES, Cotton CC, Eluri S, Shaheen NJ. Gaber CE, et al. Pharmacoepidemiol Drug Saf. 2024 Feb;33(2):e5760. doi: 10.1002/pds.5760. Pharmacoepidemiol Drug Saf. 2024. PMID: 38362648 Free PMC article.
Factors that may relate to adherence are incompletely described. METHODS: We used administrative claims data from the Merative MarketScan Commercial Claims and Encounters database to conduct a retrospective study of adherence to prescription PPIs. ...DISCUSSION: Usi …
Factors that may relate to adherence are incompletely described. METHODS: We used administrative claims data from the Merative Market …
Examining Parental Medication Adherence as a Predictor of Child Medication Adherence in Pediatric Anxiety Disorders.
Bushnell GA, Brookhart MA, Gaynes BN, Compton SN, Dusetzina SB, Stürmer T. Bushnell GA, et al. Med Care. 2018 Jun;56(6):510-519. doi: 10.1097/MLR.0000000000000911. Med Care. 2018. PMID: 29668649 Free PMC article.
BACKGROUND: Selective serotonin reuptake inhibitors (SSRIs) are the recommended first-line pharmacotherapy for pediatric anxiety disorders but adherence remains difficult to predict. OBJECTIVES: To estimate SSRI adherence in children with anxiety disorders and deter …
BACKGROUND: Selective serotonin reuptake inhibitors (SSRIs) are the recommended first-line pharmacotherapy for pediatric anxiety disorders b …
Changes in chronic medication adherence, costs, and health care use after a cancer diagnosis among low-income patients and the role of patient-centered medical homes.
Spees LP, Wheeler SB, Zhou X, Amin KB, Baggett CD, Lund JL, Urick BY, Farley JF, Reeder-Hayes KE, Trogdon JG. Spees LP, et al. Cancer. 2020 Nov 1;126(21):4770-4779. doi: 10.1002/cncr.33147. Epub 2020 Aug 11. Cancer. 2020. PMID: 32780539 Free PMC article.
The authors first evaluated the impact of a cancer diagnosis on chronic medication adherence among patients with Medicaid coverage and, second, whether PCMHs influenced outcomes among patients with cancer. ...Using difference-in-difference methods, the authors examined …
The authors first evaluated the impact of a cancer diagnosis on chronic medication adherence among patients with Medicaid coverage an …
52 results